Wacker Chemie’s Wacker Biotech entered a strategic collaboration with Eclipsebio to expand end-to-end RNA therapeutics development through GMP manufacturing.
Eclipsebio will provide AI-driven RNA design, optimization, sequencing-based characterization to improve manufacturability, yield, stability, purity, protein expression.
Wacker Biotech will supply GMP-compliant plasmid DNA, RNA, lipid nanoparticles, supporting scale-up from in vitro transcription to encapsulation for clinical use.
Partnership targets RNA developers needing early candidate design through clinic-ready production, strengthening Wacker Biotech’s contract research services offering.
XLV•
